MCAS
Aberrant mast-cell mediator release; calm immune signaling WITHOUT triggering degranulation.
Decision support, not prescription. You decide.
Contraindication — Cationic peptides can worsen MCAS (MRGPRX2 degranulation)
LL-37, VIP/PACAP and full α-MSH degranulate human mast cells via MRGPRX2 — avoid in mast-cell patients. KPV is safe (NF-κB pathway).
Candidate agents
4 agents · ranked by role, then evidenceAnti-inflammatory via NF-κB; does NOT trigger MRGPRX2 degranulation — cleanest MCAS candidate.
PMID 199097466 reports · Reduced flushing, GI flares, heat intolerance; calmer; slowed HR
Contraindication — Cationic peptides can worsen MCAS (MRGPRX2 degranulation)
LL-37 activates and recruits human mast cells (chemotaxis in the cited ref; MRGPRX2 degranulation shown in related work) — a mast-cell activator, contraindicated in MCAS.
PMID 119726283 reports · Community reports mast-cell FLARES; anhedonia rumor
2 reports · Community reports mast-cell degranulation — many put on hold
Matching protocol templates
Browse all →Gut healing, barrier repair, anti-inflammatory
Gut healing, immune modulation, inflammation control
Post-viral recovery, inflammation resolution, tendon repair
The platform surfaces evidence, community signal and peer outcomes with enforced cautions. It never decides treatment — the licensed clinician orders labs, writes notes, and prescribes.